---
title: "Nanjing Vazyme Biotech Co., Ltd. (688105.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688105.SH.md"
symbol: "688105.SH"
name: "Nanjing Vazyme Biotech Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T10:05:16.478Z"
locales:
  - [en](https://longbridge.com/en/quote/688105.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688105.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688105.SH.md)
---

# Nanjing Vazyme Biotech Co., Ltd. (688105.SH)

## Company Overview

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and cell and protein research reagents. It also provides NGS library preparation reagents, such as DNA sequencing, RNA sequencing, target capture sequencing, epigenetics, magnetic beads, NGS library quantification, and single-cell sequencing; reagents for biomedicine, including mRNA vaccine/drug key components, drug discovery tools, ELISA kits vaccine evaluation reagents, and semaglutide drug key components; instruments, including automated liquid handling workstation, automatic nucleic acid isolation system, real-time fluorescence quantitative PCR system, fluorescence quantimeter, and micro horizontal centrifuge; lab consumables for equipment comprising robotic pipette tips, robotic microwell plates, robotic deep well plates, and 96-well flat-bottom microplates; and monkeypox solutions. The company was founded in 2012 and is headquartered in Nanjing, China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.vazyme.com](https://www.vazyme.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.54)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 41 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.84% |  |
| Net Profit YoY | 32.98% |  |
| P/B Ratio | 2.18 |  |
| Dividend Ratio | 0.72% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8283609109.87 |  |
| Revenue | 1416063149.16 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -0.37% | D |
| Profit Margin | -1.01% | D |
| Gross Margin | 71.04% | A |
| Revenue YoY | 3.84% | C |
| Net Profit YoY | 32.98% | B |
| Total Assets YoY | -3.14% | D |
| Net Assets YoY | -2.77% | D |
| Cash Flow Margin | -1462.02% | E |
| OCF YoY | 3.84% | C |
| Turnover | 0.27 | D |
| Gearing Ratio | 25.65% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Nanjing Vazyme Biotech Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3.84%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "32.98%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.18",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.72%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8283609109.87",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1416063149.16",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-0.37%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-1.01%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "71.04%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "3.84%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "32.98%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.14%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-2.77%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-1462.02%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "3.84%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.27",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "25.65%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -576.57 | 82/81 | - | - | - |
| PB | 2.18 | 30/81 | 2.40 | 2.28 | 2.09 |
| PS (TTM) | 5.85 | 27/81 | 6.92 | 6.47 | 5.92 |
| Dividend Yield | 0.72% | 28/81 | 0.80% | 0.76% | 0.71% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-01T16:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 67% |
| Overweight | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 20.81 |
| Highest Target | 28.00 |
| Lowest Target | 25.47 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688105.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688105.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688105.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**